Story · Medicine & Biotech
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
2 outlets · first reported by Financial Times Health on · latest · 14 hours of coverage
Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector (Financial Times Health)
Coverage, in order
-
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Drugmaker’s potential acquisition of Ollin Biosciences is latest in glut of deals in biotechnology sector
-
J&J cuts $3.3bn deal to buy eye drug developer Ollin
J&J cuts $3.3bn deal to buy eye drug developer Ollin Phil.Taylor Mon, 16/11/2026 - 14:16
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.